Question: In-Class Learning-Activity (2) PHÁT A. The Following Table Reports Pharmacokinetic Data For The Drug Cefazolin. BIOAVAILABILITY (ORAL) (%) URINARY EXCRETION BOUND IN PLASMA CLEARANCE VOL DIST. HALF-LINE (%) ( Mmm) Cefazolin (Like) 90 8016 892 0.95 0.17 0.1900 LRD, Pres LRD KD Yunu Teported. Following A Single 1-3 IV (model-fitted Caor IM Dove To Healthy …

In-Class Learning-Activity (2) PHÁT A. The following table reports pharmacokinetic data for the drug Cefazolin. BIOAVAILABILITY (ORAL) (%) URINARY EXCRETION BOUND IN PLASMA CLEARANCE VOL DIST. HALF-LINE (%) ( mmm) Cefazolin (Like) 90 8016 892 0.95 0.17 0.1900 LRD, Pres LRD KD Yunu Teported. Following a single 1-3 IV (model-fitted Caor IM dove to healthy adults. Reference: Sisteid WM, et al. Mosulatum und entusim, compare pharmacokinetics in normal subjects. Antimicrob Agents Chemother, 1981.79:613-619. a. Given the information about changes in clearance and volume of distribution in pregnancy, and renal disease (RD), predict the corresponding changes in volume of distribution and half-life in the same populations Renal Disease Pregnancy ↑ Lion B. The following Table reports pharmacokinetic data for the drug Vancomycin. BIOAVAILABILITY (ORAL) URINARY EXCRETION BOUND IN PLASMA CLEARANCE VOL. DIST HALF-LIFE (mL/min/kg) (L) (hours) Vancomycin 09 79 +11 30 +11 CL0.79CL0.22 0.39 +0.06 56 +18 RD, Aged, Neo Os RD, Aged Very poorly absorbed, but used to treat Clostridium difficile and staphylococcal enterocolitis a. Given the information about changes in clearance and volume of distribution in renal disease (RD) Aged, and Obese population predict the corresponding changes in half-life in the same populations Renal Disease Aged Obese 个 1 Write the equation you used to make your decision: TE